Nanoviricides, Inc.NNVC
What Nanoviricides, Inc. does.
NanoViricides, Inc. (the “Company”, “NanoViricides”, “we,” or “us”) was incorporated in Nevada on April 1, 2005, and redomiciled to Delaware effective May 30, 2023. Our corporate offices are located at 1 Controls Drive, Shelton, Connecticut 06484 and our telephone number is (203) 937-6137. Our Website is located at http://www.Nanoviricides.com . We do not incorporate by reference into this Annual Report the information on or accessible through our website, and you should not consider it part of this Annual Report.
On September 25, 2013, the Company’s common stock began trading on the New York Stock Exchange American under the symbol, “NNVC”.
We are a clinical stage company with our first drug ready to enter Phase II human clinical efficacy trial, having successfully completed Phase Ia/Ib human clinical safety and tolerability trial. Based on our nanoviricides™ platform technology, we also have several additional drug candidates in various stages of pre-clinical development, including IND-filing stage and late stage IND-enabling non-clinical studies. We have no customers, products or revenues to date, and may never achieve revenues or profitable operations.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | $0 | $0 | $0 |
| Net income | -$13.4M | -$8.8M | -$8.1M | -$8.6M | -$8.3M | -$9.5M |
| Free cash flow | -$6.7M | -$8.5M | -$6.2M | -$5.8M | -$6.5M | -$8.5M |
More on NNVC.
- Nanoviricides, Inc. summary
- Nanoviricides, Inc. financial statements
- Nanoviricides, Inc. key metrics
- Nanoviricides, Inc. health scores and style box
- Nanoviricides, Inc. earnings
- Nanoviricides, Inc. dividends
- Nanoviricides, Inc. valuation
- Nanoviricides, Inc. ownership and insiders
- Nanoviricides, Inc. peers
Figures from Nanoviricides, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.